- BriaCell Therapeutics (BCT) announces proceeds of US$12.88 million from warrant exercises
- The warrants were issued as part of the units sold in BriaCell’s public offering that closed on February 26, 2021
- Proceeds will be used to advance clinical and research and development pipeline and for general corporate purposes
- BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer
- BriaCell Therapeutics Corp. (BCT) is down 3.36 per cent and is trading at C$6.91 at 11:13 am ET
BriaCell Therapeutics Corp. (BCT) has received US$12.88 million in proceeds.
Investors exercised 2,425,300 common share purchase warrants at a price of US$5.3125 per share.
The warrants were issued as part of the units sold in BriaCell’s public offering that closed on February 26, 2021.
BriaCell expects to use the net proceeds of the warrant exercises to further advance its clinical and research and development pipeline and for general corporate purposes.
“Last week, we disclosed our updated clinical survival data showing 12.0 months of overall survival benefit in advanced breast cancer patients who had previously failed a number of treatments prior to enrollment in our Phase I/IIa study,” said Dr. Bill Williams, BriaCell’s President and CEO.
“We believe that our unique technology has the potential to transform the way advanced breast cancer patients are treated, and, now with additional cash, we will be able to advance our pipeline and explore applications of our platform technology in other types of cancer in addition to breast cancer,” added Williams.
BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.
BriaCell Therapeutics Corp. (BCT) is down 3.36 per cent and is trading at C$6.91 at 11:13 am ET.
